DESCRIPTORS AND OUTCOMES FOR PATIENTS ATTENDING ENHANCED SUPPORTIVE CARE WITH LATE EFFECTS.


<u>D Monnery</u>, & H Wilson. The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, United Kingdom

Enhanced Supportive Care (ESC) is a model for delivering holistic, coordinated, multiprofessional care to patients receiving cancer treatment and beyond¹.


In the UK, it has developed to include palliative care as a central point, providing a coordination role for other supportive care specialties². As a result it is thought of as early palliative care³.


However these services in the UK are starting to support more patients with curative disease, venturing into an area of support quite outside traditional palliative care. Little is known about the efficacy of these services in the survivorship population.

Our aim is to examine the impact of an ESC approach on the delivery of symptom care for patients with late effects.




Number of Appointments	Freq	
	1	14
	2	9
	3	9
	4	8
	5	6
	6	6
7 or more		5
Median		3







Introduction



Main Reason for referral	Freq	
ocalised Pain from		
reatment (radiotherapy)		11
CIPN		17
PRD		9
AIMSS		15
atigue		1
tch		1
Dry Mouth		1
Hot Flashes		1
Cough		1
_		

ESC launched at our tertiary cancer centre in 2016, providing a holistic support model initially to patients with treatable but not curable cancer. The service began seeing patients with curative disease in 2021 and patients with late effects in 2022. In October 2023, a retrospective case note analysis was undertaken for all patients attending the ESC clinic over the previous 12 months who were referred with late effects. Data was collected relating to demographics, reasons for referral and treatment outcomes including symptom severity as recorded using IPOS.

The ESC model is effective in providing symptom relief, psychological support and addressing practical concerns following curative treatment for cancer. Common conditions seen in this service include Chemotherapy Induced Peripheral Neuropathy (CIPN), Pelvic Radiation Disease (PRD), Aromatase Inhibitor Induced Musculoskeletal Symptoms (AIMSS) and localised post radiotherapy pain. This model can work alongside other organ-specific late effects services to address the holistic aspects of late effects beyond excluding disease recurrence and addressing organ dysfunction. Further work is needed to clarify which members of the ESC team confer which outcomes with regards to the different late effects and exploring the potential role for integrative oncology in this area.

- 36997458.
- Epub 2024 Mar 27. PMID: 38557099.
- 37568675; PMCID: PMC10417474.

Method

Conclusion

References

Monnery D, Tredgett K, Hooper D, Barringer G, Munton A, Thomas M, Vijeratnam N, Godfrey N, Summerfield L, Hawkes K, Staley P, Holyhead K, Liu Y, Lockhart J, Bass S, Tavabie S, White N, Stewart E, Droney J, Minton O. Delivery Models and Health Economics of Supportive Care Services in England: A Multicentre Analysis. Clin Oncol (R Coll Radiol). 2023 Jun;35(6):e395-e403. doi: 10.1016/j.clon.2023.03.002. Epub 2023 Mar 11. PMID:

Monnery D, Droney J. Enhanced supportive care. Br J Hosp Med (Lond). 2024 Mar 2;85(3):1-8. doi: 10.12968/hmed.2023.0416.

Scotté F, Taylor A, Davies A. Supportive Care: The "Keystone" of Modern Oncology Practice. Cancers (Basel). 2023 Jul 29;15(15):3860. doi: 10.3390/cancers15153860. PMID:

4. Adapted from: Hui D, Hoge G & Bruera E. Models of Supportive Care in Oncology. Curr Opin Oncol. 2021, 33(4); 259-266